Study for treatment of myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML)
Primary disease category: Cancer
Secondary disease categories: Leukemia & Lymphoma, Myeloma
Sponsor: Southwest Oncology Group
Protocol number: S1117
Projected enrollment dates: January 2014 to April 2020
Official study title: A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
External link(s):
UA Cancer Center Website
ClinicalTrials.gov page:
http://www.clinicaltrials.gov/show/NCT01522976